I wanted to share the results of the Freedom of Information (FoI) request today. The results speak for themselves but it is concerning that there is such disparity between prescribed medication. For the East Midlands to have funded 74 cases of dasatinib and the East of England to have prescribed none is worrying. This means that depending on which part of the country you live the clinician you see will have a different opinion on the type of drug you receive, perhaps some don’t even bother with dasatinib because of the NICE decision. This has truly become a postcode lottery.

Whilst I am in favour of personalised treatment this level of disparity is not good for patients. We are finalising our Cancer Drug Fund document that provides patients and clinicians information on how to apply for drugs through the CDF. It saddens me to think that there are areas of the UK where patients are not receiving the full range of CML treatments but I will continue to do all I can to ensure that our voice is heard.

Kris

Trusts who have dasatinib on their approved list.

Trusts who have dasatinib on their approved list.

Number of applications for dasatinib on CDF

Number of applications for dasatinib on CDF